Live feed08:01:00·773dPRReleasevia QuantisnowViiV Healthcare Announces Health Canada Approval for APRETUDE (Cabotegravir tablets and extended release injectable suspension) for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIVByQuantisnow·Wall Street's wire, on your screen.PFE· Pfizer Inc.Health Care